Orange, with media services Released on Thursday, August 19, 2021 at 1:51 p.m.
Now injecting a third dose is “like giving extra life jackets to one person already, while allowing others to drown without a life jacket,” said the WHO’s emergency director.
When France is set to launch a recall campaign in September for the most vulnerable, The World Health Organization (WHO) on Wednesday 18 August condemned the rush of rich countries for a third dose of the vaccine against Govt-19, especially since scientific data did not prove the need for a booster at this stage.
“It simply came to our notice then Current data do not indicate that recall is necessaryWHO Chief Scientist Samya Swaminathan told a news conference. He explained.
From a “moral and ethical” point of view, it is not good for rich countries to inject a third dose “while the rest of the world is waiting for their first injection,” he said. “It’s like giving extra life jackets to one person already, while we allow others to drown without a life jacket. Recovery, ”WHO Emergency Director Mike Ryan told a news conference.
Despite this WHO status, The United States announced its withdrawal campaign on Wednesday Health officials are concerned about the decline in immune protection provided by anti-Govt vaccines from Pfizer and Moderna in late September. However, the recall campaign has been suspended from approving the overdose by the United States Medicines Agency (FDA).
For his part, Israel has already launched a campaign Despite the WHO ‘s call for a ban on the practice, the third dose is in favor of the elderly. France, which is set to launch its oldest and most vulnerable campaign in mid-September, did not respond to a call from the WHO on Thursday.
WHO Director-General Tetros Adanom Capreius He called on leaders to look beyond “narrow nationalist goals.”. “I was amazed at the news that Johnson and Johnson vaccines were being assembled in South Africa and going to Europe,” he said, urging the US laboratory to give urgent priority to Africa.
He expressed his concern after a recent warning from Roche, a pharmaceutical group that recommended the use of docilisumab (marketed as octemra or roctemra), an antilukin 6 (IL6) antagonist, in June to treat severe covid forms. .
“We welcome and acknowledge Roche’s announcement of measures to address the shortage. The WHO said in a statement.
“Tv expert. Writer. Extreme gamer. Subtly charming web specialist. Student. Evil coffee buff.”